A notable example is lung cancer, where, after treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), some clones become highly resistant to TKIs, poised for proliferation when given the opportunity (Roper et al., 2020). This evidence concerns the gene EGFR and lung carcinoma.